GGrantIndex
Sort

17,828 grants matching crispr

Project 1: Phospholipid Remodeling in Ferroptosis and Cancer

$664,168
Xuejun Jiang · Sloan-Kettering Inst Can Research · P01 · FY2025 · CA

Identification and Characterization of Loci Associated with Non-alcoholic Fatty Liver Disease

$664,005
Nicholette D. Allred · Wake Forest University Health Sciences · R01 · FY2023 · DK

Sex Hormone Receptor Component And The Cell Genome

$664,002
Bert W O'Malley · Baylor College Of Medicine · R01 · FY2024 · HD

Functions, mechanisms, and therapeutic potential of fetal hemoglobin inducers

$663,980
Gerd A Blobel · Children'S Hosp Of Philadelphia · R01 · FY2019 · HL

DNA Strand Separation: A New Mechanism of DNA Recognition

$663,956
Norbert O Reich · University Of California-Santa Barbara · · FY2024 · MPS

RNA Processing Machines in Biology and Disease

$663,895
Danesh Moazed · Harvard Medical School · R35 · FY2022 · GM

CRISPR screens of population relevant genes governing toxicant resilience

$663,815
Christopher D Vulpe · University Of Florida · R01 · FY2024 · ES

Using Protein Interaction Networks and Combinatorial Screens to target KRAS driven cancer

$663,814
Peter Kent Jackson · Stanford University · U01 · FY2016 · CA

Lrp4 signaling in bone metabolism and mechanotransduction

$663,798
Alexander G Robling · Indiana University Indianapolis · R01 · FY2018 · AR

Genetics and physiology of the tsetse fly bacterial endosymbiont Sodalis glossinidius

$663,764
Mauricio Henriques Pontes · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2024 · AI

Characterizing non-coding somatic and germline variant interactions in ovarian cancer

$663,739
Simon Andrew Gayther · Cedars-Sinai Medical Center · R01 · FY2022 · CA

Assembling the Genetic Architecture of X-linked Dystonia Parkinsonism

$663,716
Michael E Talkowski · Massachusetts General Hospital · R01 · FY2024 · NS

Mitochondrial fission proteins shape platelet production and function

$663,703
Jesse Rowley · Utah State Higher Education System--University Of Utah · R01 · FY2025 · HL

Obesity in ciliopathies: How neuronal primary cilia control appetite

$663,640
Christian Vaisse · University Of California, San Francisco · R01 · FY2024 · DK

Third-party “off the shelf” mature or precursor CAR T cells to prevent or treat malignant relapse after allo HCT

$663,330
Marcel R M Van Den Brink · Sloan-Kettering Inst Can Research · R01 · FY2021 · HL

Third-party “off the shelf” mature or precursor CAR T cells to prevent or treat malignant relapse after allo HCT

$663,330
Marcel R M Van Den Brink · Sloan-Kettering Inst Can Research · R01 · FY2020 · HL

Third-party “off the shelf” mature or precursor CAR T cells to prevent or treat malignant relapse after allo HCT

$663,330
Marcel R M Van Den Brink · Sloan-Kettering Inst Can Research · R01 · FY2022 · HL

Systematic elucidation of endosomal trafficking as a therapeutic opportunity in AD using CRISPR-based functional genomics

$663,216
Martin Kampmann · University Of California, San Francisco · R01 · FY2018 · AG

Regulation of Craniofacial Development by ALX Transcription Factors

$663,200
Rulang Jiang · Cincinnati Childrens Hosp Med Ctr · R01 · FY2021 · DE

Regulation of Craniofacial Development by ALX Transcription Factors

$663,200
Rulang Jiang · Cincinnati Childrens Hosp Med Ctr · R01 · FY2023 · DE

Mitochondrial signaling dynamics in cocaine use disorder

$663,198
Antony Daniel Abraham · Research Triangle Institute · DP1 · FY2024 · DA

Perturbations of host cell signaling by a complex hepatotropic pathogen

$663,183
Alexis Kaushansky · Seattle Children'S Hospital · R01 · FY2025 · AI

Using Protein Interaction Networks and Combinatorial Screens to target KRAS driven cancer

$663,150
Peter Kent Jackson · Stanford University · U01 · FY2017 · CA

A Versatile Chemical-Genetic Approach to Determine Bases for Arrhythmogenesis and Sodium Channelopathies

$663,098
Christopher A Ahern · University Of Iowa · R01 · FY2023 · HL

Developing Innovative Cell and Gene Therapy Strategies to Treat Fanconi Anemia

$662,949
Agnieszka Czechowicz · Stanford University · R01 · FY2025 · HL